Aug. 13 at 5:50 PM
New to the PRISM Emerging Global Health Index:
Achieve Life Sciences (NASDAQ:
$ACHV ).
Achieve is approaching a potentially pivotal stretch for cytisinicline, its treatment for nicotine dependence and smoking cessation.
The company plans to resubmit its NDA in Q4 2026, with potential FDA approval anticipated in the first half of 2027 and a U.S. commercial launch to follow. Achieve also recently secured
$180 million upfront through a private placement, with up to another
$174 million tied to milestone-based warrants.
Investor attention is building as well. Morgan Stanley initiated coverage with an Overweight rating and
$13 price target, joining several firms with positive ratings on the stock.
With smoking still the leading cause of preventable death in the U.S.,
$ACHV
brings a significant public-health opportunity and a defined regulatory catalyst to the PRISM Emerging Global Health Index.
https://prismmarketview.com/companies/achieve-life-sciences-inc/
